Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): Experience with infliximab and other systemic and biologic therapies

Journal of Drugs in Dermatology

Volumn 13, Issue 12, 2014, Pages 1441-1448

  Gottlieb, Alice B ^a   Kalb, Robert E ^b   Langley, Richard G ^c   Krueger, Gerald G ^d   De Jong, Elke M G J ^e   Guenther, Lynn ^f   Goyal, Kavitha ^g   Fakharzadeh, Steven ^g   Chevrier, Marc ^g   Calabro, Stephen ^g   Langholff, Wayne ^h   Menter, Alan ⁱ  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c DALHOUSIE UNIVERSITY   (Canada)

^d UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f Guenther Dermatology Research Centre   (Canada)

^g Janssen Pharmaceutical Companies of Johnson Johnson   (United States)

^h JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

ⁱ BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; BIOLOGICAL PRODUCT; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; USTEKINUMAB; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BIOLOGICAL THERAPY; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; DISEASE REGISTRY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HIGH RISK PATIENT; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; NEOPLASM; PREDICTIVE VALUE; PSORIASIS; SYSTEMIC THERAPY; ADVERSE EFFECTS; AGED; PROCEDURES; PROPORTIONAL HAZARDS MODEL; REGISTER; RISK FACTOR; TIME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL THERAPY; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PSORIASIS; REGISTRIES; RISK FACTORS; TIME FACTORS;

EID: 84920873215     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Raho G, Koleva DM, Garattini L, Naldi L. The burden of moderate to severe psoriasis. Pharmacoeconomics 2012; 30:1005-1013.
2. Papp KA, Griffiths CEM, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from five years of follow-up. Br J Dermatol 2013; 168:844-854.
3. Reich K, Wozel G, Zheng H, et al. Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2). Br J Dermatol 2013; 168:1325-1334.
4. Leonardi C, Papp K, Strober B, et al. The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials. Am J Clin Dermatol 2011; 12:321-337.
5. Pariser DM, Leonardi CL, Gordon K, et al. Integrated safety analysis: Short-and long-term safety profiles of etanercept in patients with psoriasis. J Am Acad Dermatol 2012;67:245-256.
6. Goffe B, Papp K, Gratton D, et al. An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. Clin Ther 2005; 27:1912-1921.
7. Leonardi C, Menter A, Hamilton T, et al. Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis. Br J Dermatol 2008; 158:1107-1116.
8. Schmitt-Egenolf M. Psoriasis therapy in real life: the need for registries. Dermatology 2006; 213:327-330.
9. Silverman SL. From randomized controlled trials to observational studies. Am J Medicine 2009; 122:114-120.
10. Papp KA, Strober B, Augustin M, et al. PSOLAR: Design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. J Drugs Dermatol 2012; 11:1210-1217.
11. Dixon WG, Symmons DP, Lunt M, et al. Serious infection following antitumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007; 56:2896-2904.
12. Methotrexate [package insert]. Columbus, OH: Roxane Laboratories, Inc.; 2014.
13. Kimball AB, Pariser D, Yamauchi PS, et al. OBSERVE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasis. J Am Acad Dermatol 2013; 68:756-764.
14. Bissonnette R, Searles G, Landells I, et al. The AWARE study: Methodology and baseline characteristics. J Cutan Med Surg 2009; 13:S113-S121.
15. Inzinger M, Heschl B, Weger W, et al. Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry. Br J Dermatol 2011; 165:640-645.
16. Augustin M, Spehr C, Radtke MA, et al. German psoriasis registry PsoBest: objectives, methodology, and baseline data. J Dtsch Dermatol Ges 2014; 12:48-57.
17. Lecluse LLA, Naldi L, Stern RS, Spuls PI. National registries of systemic treatment for psoriasis and the European 'Psonet' initiative. Dermatology 2009; 218:347-356.
18. Schmitt-Egenolf M. PsoReg - the Swedish registry for systemic psoriasis treatment. Dermatology 2007; 214:112-117.
19. Lecluse LLA, Piskin G, Mekkes JR,et al. Review and expert opinion on prevention and treatment of infliximab-related infusion reactions. Br J Dermatol 2008; 159: 527-536.
20. Infliximab [package insert]. Horsham, PA: Janssen Biotech, Inc; 2013.
21. Hugh J, Van Voorhees AS, Nijhawan RI, et al. From the Medical Board of the National Psoriasis Foundation: the risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies. J Am Acad Dermatol 2014; 70:168-177.
22. Tam L-S, Kitas GD, Gonzalez-Gay MA. Can suppression of inflammation by anti-TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis? Rheumatology 2014; 53:1108-1119.
23. Wu JJ, Poon K-YT, Channual JC, Shen AY. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol 2012; 148:1244-1250.
24. Costa L, Caso F, Atteno M, et al. Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol 2014; 33:833-839.
25. Adalimumab [package insert]. North Chicago, IL: AbbVie Inc; 2013.
26. Etanercept [package insert]. Thousand Oaks, CA: Immunex Corporation; 2013.
27. Papp KA, Gottlieb AB, Naldi L, et al. Safety observations in patients with psoriasis enrolled in a large, multicenter, prospective, disease-based registry (PSOLAR): experience with ustekinumab. Br J Dermatol [In Press].
28. Galloway JB, Hyrich KL, Mercer LK, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2011; 50:124-131.
29. Germano V, Cattaruzza MS, Osborn J, et al. Infection risk in rheumatoid arthritis and spondyloarthropathy patients under treatment with DMARDs, corticosteroids and TNF- α antagonists. J Transl Med 2014;12:77.
30. Dommasch ED, Abuabara K, Shin DB, et al. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol 2011; 64:1035-1050.
31. Tan X, Feldman SR, Balkrishnan R. Infections associated with the use of tumor necrosis factor-α inhibitors in psoriasis. J Drugs Dermatol 2013; 12:e41-e45.
32. Wakkee M, de Vries E, van den Haak P, Nijsten T. Increased risk of infectious disease requiring hospitalization among patients with psoriasis: a population-based cohort. J Am Acad Dermatol 2011; 65:1135-1144.
33. Gudjonsson JE, Thorarinsson AM, Sigurgeirsson B, et al. Streptococcal throat infections and exacerbation of chronic plaque psoriasis: a prospective study. Br J Dermatol 2003; 149:530-534.